Omeros Corp (OMER) Q3 2026 Earnings Call Highlights: YARTEMLEA Sales Surge 30%
Omeros Corp (OMER) reported Q3 2026 earnings with YARTEMLEA sales up 30% QoQ to $41.8M. Net loss widened to $57.4M due to a non-cash mark-to-market loss. Operating cash flow was positive at $13.3M. The company faces delays in Europe and increased gross-to-net deductions. OMER did not provide Q4 or 2027 guidance. Pipeline programs and NTAP benefits were highlighted.
How this was made

The 30-second read
Why it matters
YARTEMLEA shows strong quarter-over-quarter growth and cash flow positivity, but Europe faces a CHMP negative opinion and management flags no near-term revenue guidance. Gross-to-net pressure is expected to persist into the high-teens range, and pipeline timelines include delays for OMS527.
Market read
Traders get a fresh mix of catalysts: strong US commercial momentum and cash flow, offset by Europe regulatory delay and worsening gross-to-net deductions, plus guidance uncertainty.
What to watch
The article notes no Q4 2026 or 2027 revenue guidance; traders may overreact to the lack of guidance without separating reimbursement education ramp and NTAP uptake timing.
Background
The piece summarizes Omeros’ Q3 2026 earnings call, focusing on YARTEMLEA commercial performance, cash flow, reimbursement mechanics (NTAP, 340B), and pipeline/regulatory updates.
Ticker impact
Omeros reports YARTEMLEA Q3 sales growth, positive operating cash flow, but also a widened GAAP loss and a CHMP negative opinion in Europe.
Likely mixed reaction, with upside from YARTEMLEA momentum offset by downside from CHMP negative opinion and higher gross-to-net deductions.
The article provides specific Q3 commercial metrics, cash flow, and explicit regulatory and pricing headwinds, which directly affect valuation and forward expectations.
Market effects
Reinforces that complement/transplant-focused biotech commercialization can be strong in the US while Europe regulatory outcomes remain a key swing factor.
Europe expansion risk increases due to CHMP negative opinion, while US adoption and reimbursement mechanics remain the primary driver.
Limited direct global macro linkage; the main global read-through is regulatory path dependency for rare-disease therapies.
Counterpoint
Gross-to-net deterioration is largely tied to 340B utilization and may be a transitional effect as care shifts outpatient, not a permanent pricing impairment.
Key entities
- companyOmeros Corp
NASDAQ-listed biotech reporting Q3 2026 earnings call highlights for YARTEMLEA and pipeline/regulatory updates.
- productYARTEMLEA (narsoplimab)
Omeros’ therapy whose Q3 sales growth and reimbursement dynamics drive the commercial narrative.
- regulatorCHMP
European committee issuing a negative opinion on the narsoplimab marketing authorization application for TA-TMA.
- reimbursement_programNTAP
New Technology Add-On Payment program providing up to $287,000 per eligible Medicare inpatient case.
- reimbursement_program340B
Program affecting gross-to-net deductions, with management expecting gross-to-net to approach the high-teens.

